SCHEMBL4979392

SCHEMBL4979392

COc1ccc(Br)nc1CO

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE4A P27815 2/20 0.39
PDE4B Q07343 2/20 0.39
PDE4C Q08493 2/20 0.39
PDE4D Q08499 2/20 0.39
NQO2 P16083 3/20 0.37
ALDH1A1 P00352 5/20 0.35
KDM4E B2RXH2 3/20 0.34
L3MBTL1 Q9Y468 1/20 0.34
HPGDS O60760 1/20 0.34
POLB P06746 2/20 0.33
S1PR1 P21453 1/20 0.33
MEN1 O00255 1/20 0.33
KMT2A Q03164 1/20 0.33
ERN1 O75460 1/20 0.33
PDE5A O76074 1/20 0.33
PDE1A P54750 1/20 0.33
PDE1B Q01064 1/20 0.33
PDE3B Q13370 1/20 0.33
PDE1C Q14123 1/20 0.33
PDE3A Q14432 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15243575 0.84 HPGDS (0.38) NQO2ALDH1A1KDM4EHPGDSPOLB
SCHEMBL29987073 0.84 HPGDS (0.38) NQO2ALDH1A1KDM4EHPGDSPOLB
SCHEMBL31214269 0.82 KEAP1 (0.36) PDE4BNQO2ALDH1A1KDM4EPOLB
SCHEMBL30865588 0.82 S1PR4 (0.33) ALDH1A1KDM4ES1PR4
SCHEMBL24992633 0.82 S1PR4 (0.33) ALDH1A1KDM4ES1PR4
SCHEMBL8785416 0.82 PDE4B (0.41) PDE4APDE4BPDE4CPDE4DNQO2
SCHEMBL17927038 0.78 CCR1 (0.45) PDE4APDE4BPDE4CPDE4DNQO2
SCHEMBL3075399 0.78 KDM4E (0.59) PDE4APDE4BPDE4CPDE4DNQO2
SCHEMBL23107301 0.75 S1PR4 (0.31) S1PR4
SCHEMBL3464749 0.75 NQO2 (0.35) NQO2ALDH1A1KDM4EL3MBTL1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3523277-B1 SUBSTITUTED PYRROLIDINES AS CFTR MODULATORS ABBVIE OVERSEAS SARL (LU) 2021-06-30 EP disclosed
EP-3523293-B1 SUBSTITUTED PYRROLIDINES AND THEIR USE IN THE TREATMENT OF CYSTIC FIIBROSIS ABBVIE OVERSEAS SARL (LU) 2021-06-16 EP disclosed
US-20190315687-A1 Substituted Pyrrolidines and Methods of Use ABBVIE S.Á.R.L. (LU) 2019-10-17 US disclosed
US-10399940-B2 Substituted pyrrolidines and methods of use ABBVIE S.Á.R.L. (LU) 2019-09-03 US disclosed
EP-3523277-A1 SUBSTITUTED PYRROLIDINES AS CFTR MODULATORS Abbvie S.a.r.l. (LU) 2019-08-14 EP disclosed
EP-3523293-A1 SUBSTITUTED PYRROLIDINES AND THEIR USE IN THE TREATMENT OF CYSTIC FIIBROSIS Abbvie S.a.r.l. (LU) 2019-08-14 EP disclosed
US-9981910-B2 Substituted pyrrolidines and methods of use ABBVIE S.Á.R.L. (LU) 2018-05-29 US disclosed
US-20180099932-A1 Substituted Pyrrolidines and Methods of Use GALAPAGOS NV (BE) 2018-04-12 US disclosed
WO-2018065921-A1 SUBSTITUTED PYRROLIDINES AS CFTR MODULATORS ABBVIE S.Á.R.L. (LU) 2018-04-12 WO disclosed
WO-2018065962-A1 SUBSTITUTED PYRROLIDINES AND THEIR USE IN THE TREATMENT OF CYSTIC FIIBROSIS AbbVie S.à.r.l. (LU) 2018-04-12 WO disclosed
US-20180099931-A1 Substituted Pyrrolidines and Methods of Use ABBVIE S.Á.R.L. (LU) 2018-04-12 US disclosed
US-20080119518-A1 1-(Piperidin-4- Yl)-1H-Indole Derivatives EISAI R&D MANAGEMENT CO., LTD. (JP) 2008-05-22 US disclosed
US-20080119518-A1 1-(Piperidin-4- Yl)-1H-Indole Derivatives EISAI R&D MANAGEMENT CO., LTD. (JP) 2008-05-22 US disclosed
US-20080119518-A1 1-(Piperidin-4- Yl)-1H-Indole Derivatives EISAI R&D MANAGEMENT CO., LTD. (JP) 2008-05-22 US disclosed
EP-1847535-A1 1-(PIPERIDIN-4-YL)-1H-INDOLE DERIVATIVE Eisai R&D Management Co., Ltd. (JP) 2007-10-24 EP disclosed
EP-1847535-A1 1-(PIPERIDIN-4-YL)-1H-INDOLE DERIVATIVE Eisai R&D Management Co., Ltd. (JP) 2007-10-24 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080119518-A1 1-(Piperidin-4- Yl)-1H-Indole Derivatives TPH1, HTR1D, HTR1B PDE4A 1073/4885PDE4B 891/4885PDE4C 1343/4885
US-20180099931-A1 Substituted Pyrrolidines and Methods of Use CFTR, PKD1, PKD2 PDE4A 218/4885PDE4B 145/4885PDE4C 286/4885
US-20190315687-A1 Substituted Pyrrolidines and Methods of Use CFTR, PKD1, PKD2 PDE4A 237/4885PDE4B 159/4885PDE4C 307/4885
US-10399940-B2 Substituted pyrrolidines and methods of use CFTR, PKD1, PKD2 PDE4A 237/4885PDE4B 159/4885PDE4C 307/4885
US-20180099932-A1 Substituted Pyrrolidines and Methods of Use CFTR, PKD1, PKD2 PDE4A 237/4885PDE4B 159/4885PDE4C 307/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.